Nasal Drug Delivery Systems Market Latest Trends By Market Analysis with Top Players Merck, GlaxoSmithKline, AstraZeneca, Johnson & Johnson, Pfizer, Baxter International

The regional nasal drug delivery systems market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa by Coherent Market Insights. North America nasal drug delivery systems market is estimated to hold dominant position in 2017. The factors attributed to growth of the North America in nasal drug delivery systems market is increasing research and development by local manufacturers to develop new drug device or delivery system combination. For instance, Impel NeuroPharma, Inc., a Seattle-based clinical stage biotechnology company, is engaged in applying its Precision Olfactory Delivery (POD) nasal drug delivery platform for drugs such as levodopa powder, insulin liquid, and olanzapine powder for the treatment of Parkinson’s disease, Alzheimer’s disease and agitation in schizophrenia and bipolar disorder, respectively.

However, Asia Pacific nasal drug delivery systems market is expected to witness rapid growth, owing to increasing prevalence of diseases, which are expected to be treated by intranasal route of drug delivery. For instance, according to Journal of Allergy and Clinical Immunology, 2017, the prevalence of asthma in developed cities of Asia Pacific such as Hong Kong, Japan, and Singapore is as high as 12.4%. Key players are targeting high patient pool in this region for further growth, which is not expected in matured markets such as North America and Europe.

The major players operating in nasal drug delivery systems market are Merck & Co., GlaxoSmithKline plc, AstraZeneca plc, Johnson & Johnson, Pfizer Inc., Baxter International, Inc., Valeant Pharmaceuticals International, Inc., Becton, Dickinson and Company, and Novartis AG.

Request A Sample Copy:
https://www.coherentmarketinsights.com/insight/request-sample/1944

Nasal drug delivery system is an alternative to invasive administrations and provides direct access to systemic circulation. Intranasal drug delivery is common and most preferred route of administration in treatment of allergic and non-allergic rhinitis, pain, acute treatment of migraine, and nasal congestion associated with sinusitis, common cold or rhinitis. Nasal drug delivery are mostly used in case wherein rapid onset of action is required, or to reach the site where other route of administration displays ineffective results. Nasal drug delivery is also preferred route for needle-free vaccination and systemic drug delivery. Liquid nasal preparations can be administered through inhalers, droppers, spray pumps, nebulizers or atomizers.

The global nasal drug delivery systems market size is estimated to be valued at US$ 48.1 billion in 2018 and is expected to witness a CAGR of 6.3% over the forecast period (2018 – 2026).

Nasal cavity is becoming one of the most potential and promising route of drug delivery, owing to its advantages such as bypassing the hepatic first-pass metabolism, and most importantly patient convenience. The report provides in depth understanding of developing intranasal formulation to achieve better therapeutic objective, in turn drive the market share. However, the report also focuses on the practical and technical factors which remains the hindrance for the global nasal drug delivery system market growth over the forecast period. Furthermore, report tracks and forecast the market growth of each segment for the period of 2016-2026.

Market Dynamics

The major factors driving growth of the nasal drug delivery systems market includes, increasing product launches coupled with technologically advanced drug delivery systems and increasing incidence of nasal cavity associated diseases. For instance, in June 2018, Insys Therapeutics, Inc., a specialty pharmaceutical company, conducted clinical trial for epinephrine nasal spray, an alternative for intramuscular injection for the indication of anaphylaxis. Furthermore, companies have large number of pipeline drugs, which are to be delivered intranasally such as Acerus Pharmaceuticals Corporation is investigating TEFINA, a testosterone nasal gel, for addressing the unmet treatment demand for female sexual dysfunction. However, intranasal route of drug delivery is not suitable for all drug types, which is expected to be a major restrain for growth of the nasal drug delivery systems market.

Download the PDF brochure:
https://www.coherentmarketinsights.com/insight/request-pdf/1944

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.